Clinical intelligence
Pipeline watch
Clinical-stage assets, trial phases, expected catalysts and the uncertainties that matter most.
| Asset | Sponsor | Phase | Indication | Next catalyst | Timing | Main risk |
|---|---|---|---|---|---|---|
| Retatrutide | Eli Lilly and Company | Phase 3 | Obesity | Primary endpoint readout | Expected 2026 | Adverse effects vary by product and indication |
| CagriSema | Novo Nordisk | Phase 3 | Obesity | Enrollment or program update | Expected 2026 | Adverse effects vary by product and indication |
| Cagrilintide | Novo Nordisk | Phase 3 | Obesity | Primary endpoint readout | Expected 2026 | Adverse effects vary by product and indication |
| Survodutide | Boehringer Ingelheim / Zealand Pharma | Phase 3 | Obesity | Enrollment or program update | Date not confirmed | Adverse effects vary by product and indication |
| Maridebart cafraglutide | Amgen | Phase 3 | Obesity | Primary endpoint readout | Date not confirmed | Adverse effects vary by product and indication |
| VK2735 | Viking Therapeutics | Phase 3 | Obesity | Enrollment or program update | Date not confirmed | Adverse effects vary by product and indication |
| Pemvidutide | Altimmune | Phase 2/3 | Obesity | Primary endpoint readout | Date not confirmed | Adverse effects vary by product and indication |
| Amycretin | Novo Nordisk | Phase 2 | Obesity | Enrollment or program update | Date not confirmed | Adverse effects vary by product and indication |